BioStem Co., Ltd.

The Oncotype DX® portfolio includes genomic cancer tests for breast cancer, colon cancer, and prostate cancer. These tests apply advanced genomic science to reveal the unique biology of an individual tumor and help support more personalized cancer treatment decisions.
The Oncotype DX® tests have helped guide treatment decisions for more than 1 million cancer patients worldwide.
The Oncotype DX Breast Recurrence Score® Assay is the only breast cancer genomic test shown to predict the likelihood of chemotherapy benefit, helping physicians and patients make more informed decisions about breast cancer treatment.
For more information, please visit http://www.oncotypedxtest.com
READ MORE

NutriPATH is a privately owned medical laboratory founded in 2011. As a specialty clinical laboratory, NutriPATH pioneers a systems-based approach to health and wellbeing pathology testing, supporting healthcare providers with advanced diagnostic testing services.
NutriPATH’s testing services help general practitioners and other healthcare professionals identify the underlying causes of illness, while also providing tools to support disease prevention, healthy ageing, and proactive health management.
At NutriPATH, service excellence, innovation, teamwork, and commitment are central to every aspect of its work and daily interactions.
For more information, please visit https://nutripath.com.au/.
READ MORE